An interventional study of Gastric glucose and GLP-1(7-36)NH2 in Obesity, Normal Weight and Glucose Intolerance, sponsored by University of Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of Copenhagen · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Obesity by University of Copenhagen — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Copenhagen.
Among the 84 studies in Obesity by University of Copenhagen, this one is the 31st largest by planned enrollment of the 78 interventional ones that give a count, is one of 2 that started in 2026, is one of 71 with no phase, and was the 84th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 84 studies in Obesity by University of Copenhagen are open now, in 1 country. Recruiting first, the newest first:
University of Copenhagen · Sites in Denmark
Ages 18–40 · Healthy volunteers
University of Copenhagen · Sites in Denmark
Ages 6–12 · Healthy volunteers
University of Copenhagen · Sites in Denmark
Ages 18–75 · Men only · Healthy volunteers
University of Copenhagen · Sites in Denmark
Ages 18–65 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 50 across the 78 interventional studies, 205 across the 6 observational. Of the 71 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Copenhagen is the lead sponsor of 466 studies on the registry; 64 are open to participants now.
1 of the studies in Obesity by University of Copenhagen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07692646University of CopenhagenThe Effect of Fasting on Peak Fat Oxidation, Mitochondrial Coupling and Extracellular Matrix | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 84 studies in Obesity by University of Copenhagen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn how the gut hormone glucagon-like peptide-1 (GLP-1) helps the brain sense sugar. It includes adults with healthy weight and adults with obesity.
The main questions this trial aims to answer are:
A. Does GLP-1 cause the brain's response to sugar? B. Do lower GLP-1 levels cause a weaker brain response to sugar in adults with obesity?
Researchers will compare each participant's brain response across four test days. On these days, GLP-1 levels will be blocked, raised, or left unchanged. Sugar will be given either into the stomach or into a vein.
Participants will:
Attend 1 screening visit Visit the clinic for 4 test days Receive sugar and get an MRI scan of their brain on each test day
Inclusion Criteria:
Group 1:
Group 2:
Exclusion Criteria:
Known serious chronic disease, including but not limited to:
to study procedures, including:
Exclusion criteria for women:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant completes all four experimental conditions. Gastric glucose administration is conducted on the first test day; the following three test days are performed in randomized order.
Other: Gastric glucose · Other: GLP-1(7-36)NH2 · Other: Exendin(9-39)NH2 · Other: Isoglycemic intravenous glucose infusion
Each participant completes all four experimental conditions. Gastric glucose administration is conducted on the first test day; the following three test days are performed in randomized order.
Other: Gastric glucose · Other: GLP-1(7-36)NH2 · Other: Exendin(9-39)NH2 · Other: Isoglycemic intravenous glucose infusion
Gastric glucose administration with intravenous saline infusion.
GLP-1(7-36)NH2 infusion with gastric glucose administration.
Exendin(9-39)NH2 infusion with gastric glucose administration.
Glucose infusion with rate adjustment to replicate the individual plasma glucose excursion observed during gastric glucose administration on test day 1.
Hypothalamic response to glucose ingestion during GLP-1 receptor blockade compared with saline
Blood oxygen level-dependent (BOLD) time series are extracted from the hypothalamus and expressed relative to the BOLD signal during fasting. The hypothalamic response to glucose ingestion is defined as the relative difference between the gastric glucose condition and the isoglycemic intravenous glucose condition, pre-specified as the net area under the curve (netAUC). This outcome is reported as the difference between conditions in each group, and compared between groups.
Time frame: During the MRI scan on three test days
Hypothalamic response to glucose ingestion during GLP-1 infusion compared with saline
Blood oxygen level-dependent (BOLD) time series are extracted from the hypothalamus and expressed relative to the BOLD signal during fasting. The hypothalamic response to glucose ingestion is defined as the relative difference between the gastric glucose condition and the isoglycemic intravenous glucose condition, pre-specified as the net area under the curve (netAUC). This outcome is reported as the difference between conditions in each group, and compared between groups.
Time frame: During the MRI scan on three test days
Ad libitum energy intake
Energy intake at an ad libitum meal, recorded as an objective measure of satiety, reported as the difference between conditions within each group.
Time frame: After the MRI scan on four test days
Subjective appetite sensations
Appetite sensations rated on visual analogue scales (0-100 mm; higher scores indicate a stronger sensation), reported as the difference between conditions within each group.
Time frame: Immediately before and immediately after the MRI scan on four test days
T2 relaxation time in the mediobasal hypothalamus
T2 relaxation time is measured in the mediobasal hypothalamus using a T2-weighted sequence previously validated for quantification of hypothalamic gliosis. Longer T2 relaxation time indicates greater gliosis.
Time frame: During the MRI scan on one of four test day
Plasma glucose concentration
Glucose concentration (mmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.
Time frame: Fasting baseline and during the MRI scan on four test days
Plasma GLP-1 concentration
GLP-1 concentration (pmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.
Time frame: Fasting baseline and during the MRI scan on four test days
Plasma insulin concentration
Insulin concentration (pmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.
Time frame: Fasting baseline and during the MRI scan on four test days
Plasma C-peptide concentration
C-peptide concentration (pmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.
Time frame: Fasting baseline and during the MRI scan on four test days
Plan to share: Yes — Data sharing will be in accordance with EU and General Data Protection Regulation requirements and applicable local regulations, and in accordance with trial protocol and statistical analysis plan.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.